Back to Search Start Over

Association of Cardiometabolic Multimorbidity With Mortality The Emerging Risk Factors Collaboration

Authors :
Di Angelantonio, Emanuele
Kaptoge, Stephen
Wormser, David
Willeit, Peter
Butterworth, Adam S.
Bansal, Narinder
O'Keeffe, Linda M.
Gao, Pei
Wood, Angela M.
Burgess, Stephen
Freitag, Daniel F.
Pennells, Lisa
Peters, Sanne A.
Hart, Carole L.
Haheim, Lise Lund
Gillum, Richard F.
Nordestgaard, Borge G.
Psaty, Bruce M.
Yeap, Bu B.
Knuiman, Matthew W.
Nietert, Paul J.
Kauhanen, Jussi
Salonen, Jukka T.
Kuller, Lewis H.
Simons, Leon A.
van der Schouw, Yvonne T.
Barrett-Connor, Elizabeth
Selmer, Randi
Crespo, Carlos J.
Rodriguez, Beatriz
Verschuren, W. M. Monique
Salomaa, Veikko
Svardsudd, Kurt
van der Harst, Pim
Bjorkelund, Cecilia
Wilhelmsen, Lars
Wallace, Robert B.
Brenner, Hermann
Amouyel, Philippe
Barr, Elizabeth L. M.
Iso, Hiroyasu
Onat, Altan
Trevisan, Maurizio
D'Agostino, Ralph B., Sr.
Cooper, Cyrus
Kavousi, Maryam
Welin, Lennart
Roussel, Ronan
Hu, Frank B.
Sato, Shinichi
Davidson, Karina W.
Howard, Barbara V.
Leening, Maarten
Rosengren, Annika
Dorr, Marcus
Deeg, Dorly J. H.
Kiechl, Stefan
Stehouwer, Coen D. A.
Nissinen, Aulikki
Giampaoli, Simona
Donfrancesco, Chiara
Kromhout, Daan
Price, Jackie F.
Peters, Annette
Meade, Tom W.
Casiglia, Edoardo
Lawlor, Debbie A.
Gallacher, John
Nagel, Dorothea
Franco, Oscar H.
Assmann, Gerd
Dagenais, Gilles R.
Jukema, J. Wouter
Sundstrom, Johan
Woodward, Mark
Brunner, Eric J.
Khaw, Kay-Tee
Wareham, Nicholas J.
Whitsel, Eric A.
Njolstad, Inger
Hedblad, Bo
Wassertheil-Smoller, Sylvia
Engstrom, Gunnar
Rosamond, Wayne D.
Selvin, Elizabeth
Sattar, Naveed
Thompson, Simon G.
Danesh, John
Epidemiology
Interne Geneeskunde
MUMC+: MA Interne Geneeskunde (3)
RS: CARIM - R3 - Vascular biology
Source :
JAMA-Journal of the American Medical Association, 314(1), 52-60. American Medical Association
Publication Year :
2015

Abstract

IMPORTANCE The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS Age-and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689 300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128 843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499 808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES All-cause mortality and estimated reductions in life expectancy. RESULTS In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.

Details

ISSN :
00987484
Database :
OpenAIRE
Journal :
JAMA-Journal of the American Medical Association, 314(1), 52-60. American Medical Association
Accession number :
edsair.dedup.wf.001..900462e39167a27c1a988d89ba747849